Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

Trine Trab, Iman Chanchiri, Ahmed Al-Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Simon Husby, Michael Roost Clausen, Thomas Stauffer Larsen, Andriette C Desseau-Arp, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Peter de Nully Brown, Tarec Christoffer El-Galaly, Kirsten Gronbaek

Blood (2024) 144 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2024-201293

Published: 2024

Journal Articles

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Emil Ramsø Kyvsgaard, Morten Grauslund, Lene Sjö, Linea Melchior, Trine Grantzau, Lise Mette Gjerdrum, Trine Trab, Lærke Sloth Andersen, Anne Ortved Gang, Marie Fredslund Breinholt, Michael Boe Møller, Jacob Haaber Christensen, Thomas Stauffer Larsen, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Kirsten Gronbaek, Martin Hutchings, Simon Husby

Blood (2024) 144 (Supplement 1): 1594.

https://doi.org/10.1182/blood-2024-204772

Published: 2024

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2024-205671

Published: 2024

Journal Articles

Immunohistochemical Tumor Expression Predicts Response to CD3xCD20 Bispecific Antibodies in Patients with Relapsed/Refractory B Cell Lymphoma

Emil Ramsø Kyvsgaard, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Lene Sjö, Kirsten Grønbæk, Martin Hutchings, Simon Husby

Blood (2023) 142 (Supplement 1): 6113.

https://doi.org/10.1182/blood-2023-178315

Published: 2023

Journal Articles

CD3xCD20 Bispecific Antibodies Yields Long-Term Survival in Relapsed/Refractory B Cell Lymphoma: A Follow-up Study of Patients Treated in Pivotal Phase 1/2 Trials

Emil Ramsø Kyvsgaard, Michael Roost Clausen, Anna Caroline Hasselbalch Riley, Carsten Utoft Niemann, Kirsten Grønbæk, Martin Hutchings, Simon Husby

Blood (2023) 142 (Supplement 1): 618.

https://doi.org/10.1182/blood-2023-178323

Published: 2023

Journal Articles

Low Mortality from COVID-19 Infection in Patients with B-Cell Lymphoma after Bispecific CD20xCD3 Therapy

Emil Ramsø Kyvsgaard, Anna Caroline Hasselbalch Riley, Michael Roost Clausen, Mads Harsløf, Line Dam Heftdal, Carsten Utoft Niemann, Kirsten Grønbæk, Martin Hutchings, Simon Husby

Blood (2023) 142 (Supplement 1): 4501.

https://doi.org/10.1182/blood-2023-178321

Published: 2023

Journal Articles

Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score

Ruth Salim, Simon Husby, Christian Winther Eskelund, David W. Scott, Harald Holte, Arne Kolstad, Riikka Räty, Sara Ek, Mats Jerkeman, Christian H. Geisler, Lasse Sommer Kristensen, Mette Dahl, Kirsten Grønbæk

Blood (2022) 140 (Supplement 1): 9254–9256.

https://doi.org/10.1182/blood-2022-159472

Published: 2022

Journal Articles

Acquired Loss of a Sex Chromosome Is a Positive Prognostic Factor for Patients with Multiple Myeloma Undergoing ASCT

Simon Husby, Morten Tulstrup, Mads Harsløf, Christian Nielsen, Marianne Antonius Jakobsen, Eva Kannik Hastrup, Lene Hyldahl Ebbesen, Mette Klarskov Andersen, Maroulio Pertesi, Björn Nilsson, Carsten Utoft Niemann, Agoston Gyula Szabo, Niels Frost Andersen, Niels Abildgaard, Kirsten Grønbæk, Annette Juul Vangsted

Blood (2022) 140 (Supplement 1): 4832–4833.

https://doi.org/10.1182/blood-2022-169982

Published: 2022

Journal Articles

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Simon Husby, Gustav Ørting Jørgensen, Francesco Favero, Jakob Schmidt Jespersen, German G.R. Gonzalez, Christian Nielsen, Betina Sørensen, Lene Hyldahl Ebbesen, John Bæch, Eva Kannik Hastrup, Pär L. Josefsson, Michael Thorsgaard, Tarec Christoffer El-Galaly, Peter de Nully Brown, Thomas Stauffer Larsen, Joachim Weisenfeldt, Kirsten Grønbæk

Blood (2021) 138 (Supplement 1): 3942.

https://doi.org/10.1182/blood-2021-145417

Published: 2021

Journal Articles

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

Christian Winther Eskelund, Simon Husby, Francesco Favero, Tobias Wirenfeldt Klausen, Francisco German Rodriguez-Gonzalez, Arne Kolstad, Lone Bredo Pedersen, Riikka Katariina Räty, Christian H. Geisler, Mats Jerkeman, Joachim Weischenfeldt, Kirsten Grønbæk

Blood (2020) 135 (22): 2000–2004.

https://doi.org/10.1182/blood.2019003539

Published: 2020

Includes: Supplemental data

Journal Articles

Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality

Jakob Werner Hansen, Dorthe Almind Pedersen, Lisbeth Aagaard Larsen, Simon Husby, Signe Bedsted Clemmensen, Jacob Hjelmborg, Francesco Favero, Joachim Weischenfeldt, Kaare Christensen, Kirsten Grønbæk

Blood (2020) 135 (4): 261–268.

https://doi.org/10.1182/blood.2019001793

Published: 2020

Includes: Supplemental data

Journal Articles

A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies

Mette Dahl, MD, Simon Husby, MD, Christian Winther Eskelund, MD, Christophe Côme, PhD, Sara Ek, PhD Professor, Arne Kolstad, MD PhD, Riikka Räty, PhD Associate professor, Mats Jerkeman, MD Professor, Christian H. Geisler, MD PhD, Lasse Sommer Kristensen, PhD Assistant professor, Kirsten Grønbæk, Professor, MD DMSc

Blood (2019) 134 (Supplement_1): 1495.

https://doi.org/10.1182/blood-2019-123989

Published: 2019

Journal Articles

Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study

Blood (2018) 132 (Supplement 1): 607.

https://doi.org/10.1182/blood-2018-99-109893

Published: 2018

Journal Articles

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Christian W. Eskelund, Christina Dahl, Jakob W. Hansen, Maj Westman, Arne Kolstad, Lone B. Pedersen, Carmen P. Montano-Almendras, Simon Husby, Catja Freiburghaus, Sara Ek, Anja Pedersen, Carsten Niemann, Riikka Räty, Peter Brown, Christian H. Geisler, Mette K. Andersen, Per Guldberg, Mats Jerkeman, Kirsten Grønbæk

Blood (2017) 130 (17): 1903–1910.

https://doi.org/10.1182/blood-2017-04-779736

Published: 2017

Includes: Supplemental data

Journal Articles

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

Arne Kolstad, MD PhD, Lone B Pedersen, Christian Winther Eskelund, Simon Husby, MD, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, MD PhD, Niels S. Andersen, MD PhD, Peter de Nully Brown, MD PhD, Christian H Geisler

Blood (2016) 128 (22): 146.

https://doi.org/10.1182/blood.V128.22.146.146

Published: 2016

Journal Articles

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Blood (2015) 125 (17): 2669–2677.

https://doi.org/10.1182/blood-2014-06-584193

Published: 2015

Includes: Supplemental data

Journal Articles

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

Simon Husby, MD, Lone Bredo Pedersen, Ulrik Ralfkiær, PhD-student, Christian Garde, Sara Ek, Arne Kolstad, MD PhD, Mats Jerkeman, MD PhD, Anna Laurell, Riikka Räty, Anja Pedersen, Christer Sundström, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, MD PhD, Erik Clasen-Linde, MD, Christopher Workman, PhD, Christian H Geisler, Kirsten Grønbæk, MD DMSc

Blood (2014) 124 (21): 2994.

https://doi.org/10.1182/blood.V124.21.2994.2994

Published: 2014

NARROW

Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark

NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Immunohistochemical Tumor Expression Predicts Response to CD3xCD20 Bispecific Antibodies in Patients with Relapsed/Refractory B Cell Lymphoma

CD3xCD20 Bispecific Antibodies Yields Long-Term Survival in Relapsed/Refractory B Cell Lymphoma: A Follow-up Study of Patients Treated in Pivotal Phase 1/2 Trials

Low Mortality from COVID-19 Infection in Patients with B-Cell Lymphoma after Bispecific CD20xCD3 Therapy

Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score

Acquired Loss of a Sex Chromosome Is a Positive Prognostic Factor for Patients with Multiple Myeloma Undergoing ASCT

Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality

A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies

Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only